Predictive Oncology private placements, crypto treasury

Predictive Oncology Inc. reported that it has issued a press release announcing two private placements and the adoption of a digital asset treasury strategy.

Accepted by SEC EDGAR 09/29/2025 - 09:47 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Predictive Oncology Inc. reported that it has issued a press release announcing two private placements and the adoption of a digital asset treasury strategy. The company states that it plans to maintain its existing lines of business while also pursuing this new approach to managing part of its treasury in digital assets. These updates are provided for information purposes under Regulation FD and, as described, are not being treated as filed financial information under securities law.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Predictive Oncology Inc. (POAI) disclose in this 8-K?

Predictive Oncology Inc. disclosed that it issued a press release announcing two private placements and its adoption of a digital asset treasury strategy, while continuing its current business lines.

How is Predictive Oncology Inc. changing its treasury strategy?

The company reported that it has adopted a digital asset treasury strategy, meaning it plans to pursue holding or using digital assets as part of its treasury approach alongside its existing operations.

Does Predictive Oncology Inc. plan to change its core business after this update?

No. The company stated that it intends to continue its current lines of business in addition to pursuing its digital asset treasury strategy.

What type of financings did Predictive Oncology Inc. reference?

Predictive Oncology Inc. referenced two private placements that were announced in its press release dated September 29, 2025.

Is the press release information considered filed financial information?

The company specified that the information in Item 7.01, including the attached press release, is furnished under Regulation FD and is not deemed “filed” or subject to Section 18 liabilities, unless specifically incorporated elsewhere.

Where can investors find more details about POAI’s private placements and digital asset strategy?

More details are contained in the press release attached as Exhibit 99.1 to the report, which is incorporated by reference into Item 7.01.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000144615900014461592025-09-292025-09-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 29, 2025

_______________________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-36790	33-1007393
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

91 43rd Street, Suite 110

Pittsburgh, Pennsylvania 15201

(Address of Principal Executive Offices) (Zip Code)

(412) 432-1500

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	POAI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 29, 2025, Predictive Oncology Inc. (the “Company”) issued a press release announcing two private placements and its adoption of a digital asset treasury strategy. The Company intends to continue to pursue its current lines of business in addition to the pursuit of its digital asset treasury strategy.

The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit No.		Description of Exhibits
99.1		Press Release dated September 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Predictive Oncology Inc.
Date: September 29, 2025	By:	/s/ Josh Blacher
		Josh Blacher
		Interim Chief Financial Officer